Audentes Therapeutics (BOLD) Tops Q1 EPS by 173c

Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of $0.71, $1.73 better than the analyst estimate of ($1.02).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• US Eyes 7.5% China Overcapacity Tariffs Before Xi-Trump Talks - Bloomberg
• XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
• Active options: NVDA TSLA AAPL MU INTC AMZN SPCX MSTR GOOGL AMD